API is a molecular diagnostics company focused on developing blood-based multiplex protein tests to help physicians more effectively direct patients towards current standard-of-care patient management. API has developed a proteomics platform solution to make protein-based biomarker discovery possible as a replicable, industrial application ready to be applied to multiple health diagnostic problems. The company is currently advancing several internal diagnostic development programs, and is headquartered in San Diego, CA.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/21/13 | $28,000,000 | Series C |
Domain Associates Genting Berhad Vulcan Capital | undisclosed |
